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Abstract
An accurate prognostic model of a cancer patient after treatment can be useful in deciding the next course of 
treatment or efficacy of said treatment.  Gene expression microarray data has been used to predict survival times [1],
or to classify the patient as having a good/poor prognosis [2] by predicting whether the patient belongs to the class 
that will have a recurrence of cancer before or after a certain period, typically 3 or 5 years. Microarrays typically 
contain thousands of gene expression probes and a typical study may only contain a few hundred patients or less.  
Typical regression techniques will fail to generalize, suffering from the ‘Curse of Dimensionality’, resulting in an 
over-fitted model that performs very well on the training data, and very poorly or validation data. Various feature 
selection/reduction methods have been used to reduce the dimensionality of the data and improve or facilitate a 
solution [3]. Gene expression is known to be modulated by the expression of other genes, forming a so-called gene 
network or pathway.  Furthermore, several networks may affect the aggressiveness of the cancer simultaneously [4].  
While past studies have selected features based on statistical methods alone [5] or have simply included ‘known 
cancer genes’, none to our knowledge have used classification models based on ensembles of models based on 
multiple known gene networks.  Based on the data presented in Shedden, et. al. [6], this study uses a General 
Regression Neural Network (GRNN) Oracle ensemble that combines several Partial least squares (PLS) models 
trained to predict recurrence times from 12 different gene networks.  We hypothesize that it is possible to correctly 
classify recurrence by combining the results based on the gene network models. 
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1. Introduction
Having a predictive model for cancer patient prognosis can be helpful in directing the course of treatment, 
whether this is the initial course of treatment or follow on.  Cancer treatments such as radiation and chemotherapy 
can be toxic and harmful to the patient. Therefore, the treatment should only be as aggressive as necessary, but no 
less aggressive than necessary to insure the highest efficacy and best outcome.  If the prognosis of an individual 
patient is known a priori, the treatment can be tailored such that the patient will have the best chance for survival 
while suffering as few of the toxic effects of these treatments as possible, thereby increasing not only the longevity, 
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but also the quality of life of the patient.  This is the core of so-called Personalized Medicine.
Gene expression microarray data has provided a method of quickly generating a genetic profile of the malignant 
tissue by quantifying the expression of thousands of gene sequences in parallel from a single biological sample.  
Collecting genetic samples from many patients and then measuring the actual time of recurrence of cancer can 
provide information about the link between the expression of genes and the rate of disease progression.  This 
information can then be used to build a predictive model capable of providing a prognosis for an individual patient, 
aiding the physician in tailoring the treatment, thus maximizing the efficacy of the treatment while minimizing the 
toxic side effects.
Gene networks are an important area of study because they can measure possible abnormalities within a cell. 
These systems are an aggregation of DNA fragments and correlating molecular interactions from both inner and 
outer cellular environments. Expression levels of genes reflect the regulatory manner of overlying cellular cascades. 
Additionally regulatory enhancements and degradations play a vital role in various aspects of tumor growth. Being 
an indicator of tumor growth is not the only benefit of genetic networks. Genetic networks can reduce data noise by 
selective grouping via network association.
There have also been studies using various feature selection methods and machine learning classifiers used to 
classify time to recurrence or patient survival before or after a specific time period [7].  Based on previous work, we 
present a recurrence classification model based on a novel General Regression Neural Network (GRNN) based 
ensemble of Partial Least Squares (PLS) models.  This study explores the hypothesis that feature selection based on 
prior biological knowledge (gene networks), combined with the regularization provided by the dimensionality 
reduction of partial least squares model, combined with the “panel of experts” aspects of the GRNN Ensemble can 
produce good quality models of cancer recurrence that could be used as a decision aid in a clinical setting.
2. Methods
Our analysis workflow relies on PLS for modeling recurrence predictions from individual gene networks based 
on expression levels, and the GRNN Oracle for combining the PLS models and generating the final classification of 
recurrence before or after 5 years.  The evaluation metric used to evaluate the quality of the individual gene network 
recurrence models is Harrell’s Concordance Index [8].  The classification model quality is measured by receiver 
operating characteristic curve (ROC) area under the curve (AUC) [9], a generally accepted method of measuring the 
quality of a classifier.  These methods are briefly described in the subsections below.
2.1. Partial Least Squares (PLS)
PLS is similar to principal components analysis (PCA) whereby the variance in the data is used to create a new 
orthonormal basis which preserves as much variability in the data as possible.  Furthermore by restricting the 
degrees of freedom, we prevent over-fitting, thus producing a model that generalizes well.  Where PCA and PLS 
differ is in the selection of the basis vectors (principal component in PCA, latent variables in PLS).  PCA uses the 
direction of maximum variance in input space (X) (the microarray probe expression levels) as the principal 
components, while ignoring the output data (Y) (recurrence time) which is to be modeled.  PLS, on the other hand, 
uses the covariance between X and Y and selects the direction of maximum covariance between X and Y as the 
latent variables.  The PLS model can be constructed using the Nonlinear Iterative Partial Least Squares (NIPALS)
[10] algorithm followed by constructing a linear least squares model in the latent space.  
NIPALS is a constructive process which finds latent variables and projects the data into the latent variable thus 
creating a new ‘latent’ space one dimension at a time.  The information is then removed from the original space 
‘deflating’ one dimension at a time by projecting the data onto the subspace orthogonal to the latent variable.  This 
is repeating as up to d times, where d is the dimensionality of the input space. The geometric interpretation of the 
deflation process is shown in Fig. 1a.  The NIPALS algorithm is shown in Fig. 1b, but the reader is encouraged to 
read [10] for a more in-depth discussion on the topic. 
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Fig. 1. (a) Geometric representation of 'deflation'.  Here the black axes represent the basis of the input space.  The red line is the line spanned by 
the vector pointing in the direction of maximum covariance between X and Y (latent vector). One dimension is created in the latent space by 
projecting the data onto the latent vector (red dots). One dimension is removed from the data by projecting all data onto the subspace (orange 
line) orthogonal to this latent vector (light blue dots). (b) NIPALS algorithm for latent space construction: 1. Compute direction of maximum 
covariance, 2. Project X onto wm.  This has the effect of ‘inflating’ the data into the new space., 3. Normalize t, 4. ‘Deflate’ X, 5. ‘Deflate’ y, 6. 
Normalize y
Once the data has been projected into the latent space, a linear a least squares regression model is constructed in 
latent space.  The coefficients are computed for the model in input space and the model consists of just the 
regression coefficients which allow the model to be used in input space, eliminating the need to first transform the 
data.  Equation (7) shows the equation for computing the regression coefficients.
(7)
2.2. General Regression Neural Network Oracle Ensemble
The General Regression Neural Network Oracle is an ensemble method based on the General Regression Neural 
Network originally proposed by Spect [11], and extended by Land [12].  The GRNN is a statistical model 
formulated as a neural network.  The Oracle is an ensemble that contains several GRNN models, each modeling the 
error of the corresponding input model, and gate variables that weight the importance of each input models 
response, based on the error prediction of each GRNN. Each input model can be any regression or classification 
method and need not be of the same architecture, or even operate on the same input variables.  The only requirement 
is that the responses of the input models must be uncorrelated and that the Oracle receives the superset of all unique 
input variables.  See [12] for more information.
2.3. Receiver Operating Characteristic
The receiver operating characteristic is a well accepted method of expressing the quality of a classification 
model.  A good reference can be found in [13].
2.4. Concordance Index
Proposed by Harrell, et. al. [8], the concordance index (CI) is a generalization of the area under the ROC curve,
and similar to the ROC AUC metric, a CI of 0.5 is no better than random guessing, and a CI of 1.0 represents of 
model that predicts all outcomes perfectly.  The concordance index is determined by comparing all possible pairs of 
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predictions in the data set.  For each pair of outcomes, if the model predicts the order correctly, the pair is said to be 
concordant.  The concordance index is then the ratio of concordant pairs to all pairs.  Special consideration must 
also be taken into account if any of the cases are censored, but in our case this is not applicable.  A reasonably good 
tutorial can be found in [:
(http://www.iscb2009.info/RSystem/Soubory/Prez%20Wednesday/S23.3%20Van%20Oirbeek.pdf).
3. Data
The original data set is based on the work of Shedden et. al. [6] which contains microarray expression data 
derived from samples taken from lung adenocarcinomas.  The data contains 22,283 probes (features), from 421 
cases. A full description of this data and its origins, measurement protocols, etc. can be found in [6].
This feature-rich, case-poor data requires feature reduction before a numerical analysis can begin.  Various 
methods have been used ranging from genetic algorithms [7] to covariance structure [2].  Relying on the large pool 
of available biologically derived features, we have chosen 12 gene networks on which to base our models.  These 
gene networks were chosen because of their known biological affects on cancer growth modulation, and the 
availability of corresponding gene probes in the data set.  We originally selected several more gene networks, but 
discarded these due to one or more missing probes in the Affymetrix array data.  These gene networks can be found 
in Table 1 below. The corresponding Affymetrix probes can be found on the Affymetrix website:
(http://www.affymetrix.com/analysis/index.affx).
Table 1. Gene networks used for training the PLS models
Gene Network Genes
AKT2 Interaction AKT1,AKT2,BCL2L1,BIRC4,CASP9,CDKN1B,CHUK,IKBKB,IKBKG,NFKB1,NFKB2,
NOS3,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIK3R1,PIK3R2,PIK3R3,PIK3R5,PTEN,RELA
AKT1 Interaction AKT1,AKT2,BCL2L1,BIRC4,CASP9,CDKN1B,CHUK,IKBKB,IKBKG,NFKB1,NFKB2,NOS3,
PIAS2,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIK3R1,PIK3R2,PIK3R3,PIK3R5,PTEN,RELA
SVC2 Interaction LAMA1,LAMA2,LAMA3,LAMA4,LAMA5,LAMB1,LAMB2,LAMB3,LAMB4,LAMC1,LAMC2,LAMC3
RELA Interaction AKT1,AKT2,BCL2L1,BIRC4,CASP9,CDKN1B,CHUK,IKBKB,IKBKG,NFKB1,NFKB2,NOS3,
PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIK3R1,PIK3R2,PIK3R3,PIK3R5,PTEN,RELA
PDK1 Interaction AKT1,AKT2,AKT3,MAX,MYC,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIK3R1,PIK3R2,PIK3R3,PIK3R5
NFKB1 
Interaction
AKT1,AKT2,AKT3,BCL2,BCL2L1,BIRC2,BIRC3,BIRC4,CCND1,CHUK,E2F1,IKBKB,IKBKG,NFKB1,
NFKB2,NFKBIA,NOS1,NOS2A,NOS3,PTGS2,RELA,RXRA,TRAF1,TRAF2,TRAF3,TRAF4,TRAF5,TRAF6
CDKN1B 
Interaction
AKT1,AKT2,AKT3,CCND1,CCNE1,CCNE2,CDK2,CDK4,CDK6,CDKN1B,CKS1B,E2F1,E2F2,E2F3,
MAX,MYC,RB1,SKP2,TRAF2
EGF Receptor 
Signal Pathway
PIK3CA,PRKCA,SOS1,SOS2,PIK3CB,MAPK3,RAF1,BRAF,PIK3CG,PLCG2,NRAS,KRAS,MAPK1,AKT2,
HRAS,TGFA,MAP2K1,MAP2K2,PIK3R5,ARAF,PRKCG,AKT3,AKT1,PIK3CD,PLCG1,ERBB2,GRB2
GAB2 Interaction PIK3CA, E2F2, PIK3CB,E2F1,EGFR,MAPK3,PIK3CG, PIK3R1,PLCG2, MAPK1,PIK3R2,PIK3R5, 
AKT1,PIK3CD,E2F3,GRB2,PIK3R3
IRSI Interaction PIK3CA,E2F2,PIK3CB, E2F1,EGFR,MAPK3,PIK3CG,PIK3R1,PLCG2,MAPK1,PIK3R2,PIK3R5, 
AKT1,PIK3CD,E2F3,GRB2,PIK3R3
PDGF Signal 
Pathway
PIK3CA, PRKCA, SOS1,SOS2,PIK3CB,MAPK3,RAF1,BRAF,PDPK1,PIK3CG,PIK3R1,PLCG2, NRAS, 
KRAS,MAPK1,AKT2,HRAS,PIK3R2,MAP2K1,MAP2K2,PIK3R5,ARAF,PIK3CD,PLCG1,GRB2, PIK3R3
PDGFRB 
Interaction
AKT1, AKT2, AKT3, CCND1, CCNE1, CCNE2, CDK2, CDK4, CDK6, CDKN1B, CKS1B, E2F1, E2F2, 
E2F3, MAX, MYC, RB1, SKP2, TRAF2
4. Experimental Design
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To determine if these gene networks contained could be used as good predictors of cancer recurrence, we 
constructed one PLS model for each set of gene networks.  Due to the small sample size, we used 5 fold cross 
validation to increase the effective size of the data set.  Each set of data was divided evenly into 5 folds.  A PLS 
model was trained using 4 folds, and then evaluated by computing the concordance index on the remaining fold.  
This was repeated holding out each of the remaining 4 folds until the PLS was used to evaluate all 5 groups.
This was repeated 15 times, creating models with 1-15 latent variables.  These 15 models were compared, and the 
best performing model (i.e. the model with the highest validation concordance index) was selected for further 
processing with the ensemble. The GRNN Oracle was trained and evaluated using the identical method.  For each 
run, the sigma’s were optimized using a one-hold-out method.
5. Results and Conclusions
Surprisingly, the experimental data did not support our original hypothesis.  We found that the gene network-
based PLS models performed very poorly at predicting recurrence time.  The concordance indices (CI) for all 
models were typically less than 0.55, which is only slightly better than random guessing (CI = 0.5).  Fig. 2a shows a 
plot of the average concordance index for the 5 validation folds for each model vs. the number of latent variables.  
Fig. 2b shows the ROC AUC plot of the final ensemble prediction.  Fig. 2c shows Kaplan-Meier curves for the final 
ensemble prediction.  Note that the GRNN Oracle ensemble did improve predictive performance of any single 
model by itself, as expected.  Based on these results, we propose the following explanations, which are unsupported 
hypotheses which need to be vetted against the current literature or further experimentation.   
  
Fig. 2. (a) Plot of validation concordance index for each PLS model. Note that the legend contains the number of 
latent variables of the best performing model in parentheses. (b) ROC AUC curve for the GRNN Oracle Ensemble 
classification.  (c) Kaplan-Meier for GRNN Oracle Ensemble classification.
The data may be nonlinear.  The expressive power of the PLS model is limited due to the fact that it is a linear 
model.  If the data are nonlinear, the PLS model will be unable to capture the nonlinearities present in the data.  To 
determine this, a nonlinear model such as one of the many kernel methods (Kernelized PLS, GRNN, etc.) could be 
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used to see if there is a marked improvement in the performance of the individual input models.  If the data are 
nonlinear, a nonlinear model would have a higher validation concordance index than the current linear model.
Second, there may be more noise than signal in the data.  There have been other studies indicating that 
microarray data are inherently very noisy sources of data [9].  
The final, and most interesting explanation, is that the modulation of gene expression in a network is a dynamic 
process, constantly changing in time.  Since we have only one tissue sample from each patient, each sample 
represents one snapshot in time of this dynamic process.  Furthermore, since the data span the range of cancer 
progression (as indicated by the staging), the samples are not temporally correlated either.
To determine data nonlinearity, the experiments could be repeated, replacing the linear PLS model with a kernel 
method.  To address the weak signal hypothesis, an in depth review of the microarray literature needs to be 
conducted to guide future experimental designs to quantify the amount of signal present in the data.  Finally, to 
determine if there is a temporal correlation, the data could be divided into sub groups by stage, and the experiments 
above could be repeated to see if we can increase the predictive capability of the models.
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